Abstract: The present invention includes compounds, compositions comprising the same, and methods using the compounds and/or compositions therein, for modulating skin pigmentation in a mammalian subject. In certain embodiments, the compounds of the invention treat or prevent skin disorders or diseases associated with hyperpigmentation in the subject. In other embodiments, the compounds of the invention act as antagonist to the non-canonical sex steroid hormone receptor GPRE1 and do not bind to a canonical nuclear estrogen receptor (ER). In yet other embodiments, the compounds of the invention comprise acts as agonists to the non-canonical sex steroid hormone receptor PAQR7 and do not bind to a canonical nuclear progesterone receptor (PR).

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depressive disorder (MDD) and/or pain. The present invention is further directed to a transdermal delivery device comprising ketamine and abuse deterrent agents.

Abstract: The disclosure provides methods of treating cancer by selectively inhibiting p-S552-?-catenin, p-T217-?-catenin, p-T332-?-catenin, and/or p-S675-?-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.

Abstract: Provided is a composition for reducing hair loss and thickening hair and a preparation method thereof, and more particularly to a composition for preventing hair loss and thickening hair that includes beads composed of carrageenan, cellulose, agar, charcoal powder, acrylate copolymer, caffeine, amino acid, keratin, gellan gum, Ulva lactuca powder, menthol, salicylic acid, dexpanthenol, niacinamide, zinc pyrithione, biotin, etc.

Abstract: The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.

Abstract: Compositions for improving erectile function or treating erectile dysfunction include active ingredients of Muira Puama extract, Quercetin, Chlorophytum borivilianum (Safed Musli), Dimethylethanolamine (DMAE), niacin, Tribulus terrestris extract, alpha-lipoic acid, Horny Goat Weed (Epimedium grandfiflorum), Panax ginseng, and saw palmetto berry extract, and may also include magnesium aspartate, Zinc oxide, and Maca root (Lepidium meyenii). Additional active ingredients include Avena sativa extract (oat straw), L-Taurine, L-Lysine hydrochloride (HCl), a L-Arginine, and/or L-Carnitine.

Abstract: The present disclosure provides an antimicrobial alginate fiber, a method for manufacturing an antimicrobial alginate fiber dressing thereof, and an application thereof. When the cationic polymer polyhexamethylene guanide salt is mixed with the anionic polymer alginate, the antimicrobial activity of the guanide salt is quickly passivated. The present disclosure achieves a lower content of polyhexamethylene guanide salt in an alginate dressing with good long-term antimicrobial activities. The polyhexamethylene guanide salt has a low dissolution rate, and significantly reduces a potential risk of carcinogenicity, mutagenicity and reproductive toxicity.

Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.

Abstract: The subject invention pertains to polyacrylate homopolymers produced from acrylolated drug monomers. The homopolymers can be produced in the form of nanoparticles. The nanoparticles comprising the homopolymers can be produced via a free radical-induced emulsion polymerization of the acrylolated drug monomers to produce an aqueous emulsion of uniformly sized nanoparticles. The homopolymers of the invention containing acrylolated antibiotic monomers can be active against Gram-positive and Gram-negative bacteria, such as Staphylococcus aureus and Escherichia coil. Accordingly, methods are provided of treating a disease, for example, an infection, by administering to a subject the homopolymers, homopolymeric nanoparticles, or emulsions containing homopolymeric nanoparticles of the invention.

Abstract: A method for producing a composition comprising nanoparticles of a biologically active compound.

Abstract: The present invention is directed to palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing oral veterinary compositions. Various aspects of the present invention are related to preparing palatable veterinary compositions that comprises mixing one or more pharmaceutical active ingredients having a smell with one or more palatabilizing agents.

Abstract: In accordance with one aspect, embolic particles are provided which comprise sub-particles that comprise a therapeutic agent of low solubility dispersed in a matrix that comprises a biodegradable polymer. Other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. Still other aspects pertain to methods of making such particles.

Abstract: The present invention has the purpose of providing an oil-in-water emulsion cosmetic that contains a high quantity of an ultraviolet absorbing agent and an ultraviolet scattering agent in the oil phase and achieves a high SPF, while simultaneously having a Distinctive fresh feeling in use when applied to the skin. The present invention provides an oil-in-water emulsion cosmetic characterized by comprising (A) 0.05 to 1% by mass of a hydrophobically modified alkyl cellulose; (B) 5 to 40% by mass of an oil component; (C) 2.5 to 30% by mass of an ultraviolet scattering agent having a hydrophobic surface; and (D) a water phase thickener having low salinity tolerance; wherein the (C) ultraviolet scattering agent is dispersed in the oil phase.

Abstract: Provided herein are compositions, formulations, and (e.g., oral) dosage forms comprising a compound of Formula (I). In specific instances, such compositions comprise an emulsifier, a solubilizer, a polyethylene glycol, a surfactant, and an antioxidant. In some instances, such compositions are useful for the treatment of fibrosis, cancer, and/or chronic inflammation.

Abstract: The invention relates to a deodorant composition in the form of a solid stick comprising: a) from 24 to 55 wt. % of dipropylene glycol; b) from 4 to 8 wt. % of propylene glycol; c) from 10 to 20 wt. % of glycerol; d) from 20 to 40 wt. % of water; and, e) from 0.5 to 15 wt. % of a structurant; wherein, the weight ratio of dipropylene glycol (a), to propylene glycol (b) is greater than 5:1; and, wherein, the weight ratio of dipropylene glycol (a), to glycerol (c) is from 1:1 to 3:1.

Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

Abstract: Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

Abstract: Compositions, tablets, prills and granules are provided including (a) about 95 to about 99.999 weight percent of at least one alkali metal hydrogen sulfate; and (b) about 0.001 to less than 0.08 weight percent of at least one alkali metal salt of a fatty carboxylic acid and/or at least one alkaline earth metal salt of a fatty carboxylic acid; wherein the composition includes less than 1 weight percent of chlorite and/or hypochlorite and less than 1 weight percent of alkali metal salt and/or alkaline earth metal salt that is chemically different from the at least one alkali metal hydrogen sulfate, the at least one alkali metal salt of a fatty carboxylic acid and the at least one alkaline earth metal salt of a fatty carboxylic acid, on a basis of total weight of the composition. Methods of use also are provided.